Wall Street Zen Upgrades Femasys (NASDAQ:FEMY) to “Hold”

Femasys (NASDAQ:FEMY) was upgraded by Wall Street Zen to a “hold” rating in a research report issued on Saturday.

FEMY has been the topic of a number of other research reports. Weiss Ratings raised shares of Femasys from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, June 3rd. Lake Street Capital began coverage on shares of Femasys in a report on Tuesday, March 3rd. They issued a “buy” rating and a $30.00 price target on the stock. Three investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Femasys presently has a consensus rating of “Moderate Buy” and a consensus target price of $106.67.

Femasys Stock Performance

NASDAQ FEMY opened at $4.18 on Friday. Femasys has a 1 year low of $4.02 and a 1 year high of $22.20. The company has a debt-to-equity ratio of 0.53, a current ratio of 3.91 and a quick ratio of 1.98. The stock has a market capitalization of $12.62 million, a PE ratio of -0.77 and a beta of -2.23. The company’s 50 day simple moving average is $7.61 and its two-hundred day simple moving average is $10.96.

Femasys (NASDAQ:FEMY) last issued its quarterly earnings results on Friday, May 8th. The company reported $0.10 EPS for the quarter, topping analysts’ consensus estimates of ($1.33) by $1.43. The firm had revenue of $0.42 million for the quarter, compared to analyst estimates of $0.77 million. Femasys had a negative net margin of 521.97% and a negative return on equity of 258.08%.

Hedge Funds Weigh In On Femasys

Institutional investors and hedge funds have recently made changes to their positions in the business. Kovack Advisors Inc. bought a new position in shares of Femasys during the 4th quarter valued at $27,000. Osaic Holdings Inc. bought a new position in shares of Femasys during the 2nd quarter valued at $45,000. HRT Financial LP bought a new position in shares of Femasys during the 4th quarter valued at $30,000. Cetera Investment Advisers bought a new position in shares of Femasys during the 4th quarter valued at $36,000. Finally, State Street Corp grew its holdings in shares of Femasys by 43.5% during the 4th quarter. State Street Corp now owns 80,869 shares of the company’s stock valued at $47,000 after purchasing an additional 24,500 shares during the last quarter. Institutional investors own 65.27% of the company’s stock.

Femasys Company Profile

Femasys International, Inc is a medical device company focused on the research, development and commercialization of innovative technologies for interventional women’s health applications. The company’s core activities center on creating minimally invasive diagnostic and therapeutic products designed to address uterine cavity evaluation and treatment and to improve outcomes in gynecological care.

The company’s flagship product, the FemVue® hydrosonography system, is a single-use catheter-based device that enhances visualization of the uterine cavity through saline infusion sonography.